Free Trial
NYSE:JNJ

Johnson & Johnson (JNJ) Stock Price, News & Analysis

Johnson & Johnson logo
$159.86
-0.75 (-0.47%)
(As of 10/31/2024 ET)

About Johnson & Johnson Stock (NYSE:JNJ)

Key Stats

Today's Range
$159.46
$160.87
50-Day Range
$159.56
$167.38
52-Week Range
$143.13
$168.85
Volume
8.27 million shs
Average Volume
6.99 million shs
Market Capitalization
$384.73 billion
P/E Ratio
23.13
Dividend Yield
3.10%
Price Target
$175.93
Consensus Rating
Moderate Buy

Company Overview

Johnson & Johnson is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.





Johnson & Johnson Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
99th Percentile Overall Score

JNJ MarketRank™: 

Johnson & Johnson scored higher than 99% of companies evaluated by MarketBeat, and ranked 47th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Johnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Johnson & Johnson has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Johnson & Johnson's stock forecast and price target.
  • Earnings Growth

    Earnings for Johnson & Johnson are expected to grow by 6.24% in the coming year, from $9.94 to $10.56 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Johnson & Johnson is 23.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.66.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Johnson & Johnson is 23.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.59.

  • Price to Earnings Growth Ratio

    Johnson & Johnson has a PEG Ratio of 2.90. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Johnson & Johnson has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Johnson & Johnson's valuation and earnings.
  • Percentage of Shares Shorted

    0.78% of the float of Johnson & Johnson has been sold short.
  • Short Interest Ratio / Days to Cover

    Johnson & Johnson has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Johnson & Johnson has recently decreased by 5.47%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Johnson & Johnson pays a meaningful dividend of 3.03%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Johnson & Johnson has been increasing its dividend for 63 years.

  • Dividend Coverage

    The dividend payout ratio of Johnson & Johnson is 30.92%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 46.97% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

  • Read more about Johnson & Johnson's dividend.
  • Percentage of Shares Shorted

    0.78% of the float of Johnson & Johnson has been sold short.
  • Short Interest Ratio / Days to Cover

    Johnson & Johnson has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Johnson & Johnson has recently decreased by 5.47%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Johnson & Johnson has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 25 news articles for Johnson & Johnson this week, compared to 30 articles on an average week.
  • Search Interest

    165 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.
  • MarketBeat Follows

    49 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $930,113.00 in company stock.

  • Percentage Held by Insiders

    Only 0.16% of the stock of Johnson & Johnson is held by insiders.

  • Percentage Held by Institutions

    69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Johnson & Johnson's insider trading history.
Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Stock News Headlines

Photo of blue poker chips against a stock chart background
How to Find Blue Chip Dividend Stocks (JNJ)
Blue chip stocks are typically market leaders and have a history of paying dividends. Learn more about how to find blue chip dividend stocks with MarketBeat.
Full frame shot of composed various medical supplies on blue surface — Photo
Best Pharma Stocks for Long-Term Investors: Growth and Dividends (JNJ)
Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive.
The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
Eli Lilly weight loss
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top (JNJ)
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.
Security Symbol With Stacked Coins Over Grey Background — Photo
Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio (JNJ)
Risk-averse investors can build a stable portfolio by focusing on established companies with consistent dividends and proven track records of success.
Johnson & Johnson’s Tremfya shows efficacy in Crohn’s disease Phase 3 study
Johnson & Johnson says Impella ECP met primary endpoint in high-risk PCI study
See More Headlines

JNJ Stock Analysis - Frequently Asked Questions

Johnson & Johnson's stock was trading at $156.74 at the beginning of 2024. Since then, JNJ stock has increased by 2.0% and is now trading at $159.86.
View the best growth stocks for 2024 here
.

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings results on Tuesday, October, 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm's revenue was up 5.2% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Johnson & Johnson: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and more.

Top institutional investors of Johnson & Johnson include Raymond James & Associates (0.29%), National Pension Service (0.19%), DekaBank Deutsche Girozentrale (0.18%) and Principal Financial Group Inc. (0.14%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Peter Fasolo, William Hait, Kathryn E Wengel, Ashley Mcevoy, Thibaut Mongon, Joseph J Wolk, Robert J Decker and James D Swanson.
View institutional ownership trends
.

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), UnitedHealth Group (UNH), Gilead Sciences (GILD), Corning (GLW), NextEra Energy (NEE) and Devon Energy (DVN).

Company Calendar

Ex-Dividend for 9/10 Dividend
8/27/2024
Dividend Payable
9/10/2024
Last Earnings
10/15/2024
Today
10/31/2024
Ex-Dividend for 12/10 Dividend
11/26/2024
Dividend Payable
12/10/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
1/28/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
47816010
Employees
131,900
Year Founded
1886

Price Target and Rating

Average Stock Price Target
$175.93
High Stock Price Target
$215.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+9.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
13 Analysts

Profitability

Net Income
$35.15 billion
Pretax Margin
20.10%

Debt

Sales & Book Value

Annual Sales
$87.70 billion
Cash Flow
$13.43 per share
Book Value
$28.57 per share

Miscellaneous

Outstanding Shares
2,406,679,000
Free Float
2,403,392,000
Market Cap
$386.56 billion
Optionable
Optionable
Beta
0.52

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NYSE:JNJ) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners